Clinical trial · no report yet · Phase 3
NCT05840016
AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer
- NCT05840016 ↗
- Active not recruiting
- Akeso
- 5 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built. Commentary is thin so far, so the report would be short.
| Channel | Found | |
|---|---|---|
| X threads | 5 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Controlled, Multi-center Phase III Clinical Study of AK112 Combined With Chemotherapy Versus PD-1 Inhibitor Combined With Chemotherapy as First-line Treatment for Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Advanced Squamous Non Small Cell Lung Cancer
- Interventions
- AK112, Carboplatin, Paxlitaxel; Tislelizumab, Carboplatin, Paxlitaxel
- Arms
- Experimental: AK112 in Combination With Paclitaxel Plus Carboplatin · Experimental
- Active Comparator: Tislelizumab in Combination With Paclitaxel Plus Carboplatin · Active comparator
- Enrollment
- 532
- Primary outcomes
- PFS assessed by IRRC per RECIST v1.1
- Sponsor
- Akeso
- Start
- Aug 17, 2023
- Primary completion
- Feb 28, 2025
- Results posted
- No
- Registry record
- NCT05840016 · updated May 2, 2025
Publications
linked from the registry- Chen Z, Yang F, Jiang Z, Sun L, Wu L, Han Z, Fan Y, Zhao Y, Li X, Xu H, Meng X, Liu Y, Zhang Z, Luo H, Ma X, Ma X, Shi Q, Zhang Z, Yang R, Wang P, Pan P, Ai X, Li J, Pu X, Wang Z, Fang J, He M, He Y, Guo S, Li J, Wang H, Zhang J, Chu Q, Liu X, Ying S, Wu H, Sun H, Ji Y, Zhou M, Cao C, Tang K, Li Z, Li D, Zhang Z, Li J, Zhou J, Yang H, Du Y, Yang H, Shi J, Chen H, Moore AC, Lu S. Plain language summary: comparing ivonescimab plus chemotherapy with tislelizumab plus chemotherapy in people with advanced squamous non-small cell lung cancer in the HARMONi-6 study. Future Oncol. 2026 Jun;22(14):1637-1650. doi: 10.1080/14796694.2026.2676052. Epub 2026 Jun 3. PubMed 42233228
- Lu S, Liu B, Luo Y, Sun L, Wu L, Han Z, Fan Y, Zhao Y, Li X, Xu H, Meng X, Liu Y, Zhang Z, Luo H, Ma X, Ma X, Shi Q, Zhang Z, Yang R, Wang P, Pan P, Ai X, Li J, Pu X, Wang Z, Fang J, He M, He Y, Guo S, Li J, Wang H, Zhang J, Chu Q, Liu X, Ying S, Wu H, Sun H, Ji Y, Zhou M, Cao C, Tang K, Li Z, Li D, Zhang Z, Li J, Zhou J, Yang H, Du Y, Yang H, Shi J, Chen H, Chen Z, Li W, Lu D, Hu M, Wang ZM, Li B, Xia MY. Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China. Lancet. 2026 Jun 27;407(10548):2620-2629. doi: 10.1016/S0140-6736(26)00966-9. Epub 2026 May 31. PubMed 42218899